There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (NASDAQ:DXCM) and Revance Therapeutics (NASDAQ:RVNC) with bullish sentiments.
Dexcom (DXCM)
In a report released today, Chris Cooley from Stephens reiterated a Buy rating on Dexcom, with a price target of $135. The company’s shares opened today at $124.69, close to its 52-week high of $125.65.
According to TipRanks.com, Cooley is a 5-star analyst with an average return of 33.0% and a 75.4% success rate. Cooley covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Staar Surgical Company, and DENTSPLY SIRONA Inc.
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $126.55, a 1.5% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $150 price target.
.
See today’s analyst top recommended stocks >>
Revance Therapeutics (RVNC)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Revance Therapeutics today and set a price target of $50. The company’s shares opened today at $29.75.
Chen commented:
“. Post a solid quarter of execution in 2Q18, we reiterate our OW rating and 12-month price target of $50 on shares of RVNC. We expect upward earnings revisions to levels not reflected in sell-side consensus expectations to drive the stock higher. Revance’s long-duration, next-generation injectable neuromodulator may be a pipeline in a product. RT002 targets a $3B+ market opportunity for both medical and aesthetic indications.”
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -6.3% and a 40.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Melinta Therapeutics Inc, and Aclaris Therapeutics Inc.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $51.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
